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E-mail: t-okada@nms.ac.jpRecombinant adeno-associated virus serotype 9 (rAAV9) can
speciﬁcally transduce muscle and neuronal tissues; thus,
rAAV9 can potentially be used in gene therapy. However,
rAAV9 is the most challenging rAAV serotype to purify.
Traditionally, rAAV9 has been puriﬁed by ultracentrifugation,
which is not scalable. We recently described a chromatographic
puriﬁcation protocol for rAAV1; this protocol can achieve
scalable puriﬁcations. In this study, we attempted to optimize
this protocol for purifying rAAV9 preparations, and we devel-
oped a novel, effective method for high-yield puriﬁcation of
rAAV9 using quaternary ammonium anion exchangers and
size-exclusion chromatography. The ﬁnal puriﬁed rAAV9 con-
tained mainly three capsid proteins, as observed by SDS-
PAGE. Furthermore, negative-stain electron microscopy
demonstrated that 96.1% ± 1.1% of rAAV9 particles carried
the viral genome containing the EGFP transgene, indicating
that impurities and empty capsids can be eliminated with
our puriﬁcation protocol. The ﬁnal rAAV9 titer obtained by
our protocol totaled 2.5 ± 0.4  1015 viral genomes produced
from 3.2 109 HEK293EB cells. We conﬁrmed that our pro-
tocol can also be applied to purify other varied AAV genome
constructs. Our protocol can scale up production of pure
rAAV9, in compliance with current good manufacturing prac-
tice, for clinical applications in human gene therapy.
INTRODUCTION
Recombinant adeno-associated viruses (rAAVs) have long been
actively studied as gene delivery vectors. rAAVs generated using
different natural AAV serotypes display different tissue tropisms
in vivo; therefore, rAAVs have emerged as versatile delivery vehicles
for gene therapy.1–4 In fact, rAAVs have already shown potential in
clinical trials and have been used for treating lipoprotein lipase deﬁ-
ciency and Leber congenital amaurosis.5–7 To extend the possibility of
rAAV-based gene therapy in human, it is essential to improve the
methodologies for rAAV production and puriﬁcation. For clinical
gene therapy applications, the ﬁnal preparation of rAAV should
contain as few impurities and empty capsids as possible to avoid180 Molecular Therapy: Methods & Clinical Development Vol. 11 Decem
This is an open access article under the CC BY license (http://creatiinﬂammation and immune responses. Furthermore, puriﬁcation pro-
tocols should preferably be expandable, cost-effective, and reproduc-
ible for mass production. Conventional rAAV puriﬁcation methods
use cesium chloride (CsCl) or iodixanol density gradient ultracentri-
fugation,8,9 entailing cumbersome procedures, and are unsuitable for
large-scale puriﬁcation. Therefore, developing alternative rAAV
preparation methods is necessary to satisfy these conditions.
Chromatographic puriﬁcation is more suitable for large-scale vector
puriﬁcation than commonly used ultracentrifugation methods.
Thus, several chromatographic protocols have been proposed for pur-
ifying rAAVs.10–16 Additionally, to exclude contaminating cellular
proteins and genomic DNA while maintaining high biological activ-
ity, it is desirable to collect the secreted rAAV from culture media that
exclude serum because minimal levels of cellular or serum contami-
nants can improve the loading capacity and the puriﬁcation proced-
ure.17 Fortunately, most AAV serotypes except AAV2 are secreted by
transfected cells into the culture supernatant.17,18 We have also
demonstrated that rAAV110,11 and rAAV810 are secreted by cells
transfected with cis, trans, and helper AAV plasmids. Thus, collecting
rAAVs secreted in the culture media, which exclude serum, and their
chromatographic puriﬁcation are applicable to optimal puriﬁcation of
most AAV serotypes, resulting in high purity and high yields.
Among the AAV serotypes, rAAV9 is expected to be used widely in
human gene therapy because of its broad tissue tropism. For instance,
rAAV9 can transduce the cardiac muscles more efﬁciently than sero-
type 8.19 In addition, it can cross the blood-brain barrier.20–22 Thus,
rAAV9 is a potential therapeutic vector for cardiac, neurodegenera-
tive, and neuromuscular diseases.23 Therefore, the production ofber 2018 ª 2018 The Authors.
vecommons.org/licenses/by/4.0/).
Figure 1. Initial Two-Step Treatment of Culture Supernatant with Saturated
AS Precipitation
ASwas added to the post-tangential flow-filtration fraction (post-TFF) to achieve 1/3
saturation. AAV9-dsEGFP was finally precipitated in 1/2 AS solution (1/3/1/2 AS,
lane 5). The post-TFF was treated with half-saturated AS (1/2 AS) precipitation alone
as the conventional procedure (lane 3). Samples were analyzed by 5%–20% (v/v)
gradient gel SDS-PAGE with Q-CBB staining. M, protein size marker; lane 1, pre-
TFF; lane 2, post-TFF; lane 3, post-TFF preparation directly precipitated in 1/2 AS;
lane 4, 1/3 AS precipitate; lane 5, 1/3/1/2 AS precipitate.
www.moleculartherapy.orghigh-quality rAAV9 particles will have a substantial effect on gene
therapy. In this study, we have established a simple, ultracentrifuga-
tion-free protocol for the production of large quantities of highly
pure rAAV9 preparations. In our protocol, the cell culture medium,
which excludes serum, is applied to a quaternary ammonium anion
exchanger, yielding highly pure rAAVs that can be veriﬁed by detect-
ing its three major AAV capsid proteins by SDS-PAGE. An important
modiﬁcation is the use of the supernatant derived from HEK293 EB
cells (HEK293 cells expressing the E1 gene region [E1A, E1B19K, and
E2A] and the BCL-XL gene)
24 transfected with the AAV cis, trans, and
helper plasmids to produce high yields of rAAV9. Most of the
contaminants and empty capsids in the culture supernatant can be
separated from puriﬁed rAAV9 by this easy puriﬁcation method.
Thus, our simple protocol is capable of producing high-quality
rAAV9 with a high manufacturing yield.Molecular TheRESULTS
Precipitation of rAAV9 by Ammonium Aulfate
Previously, we successfully used ammonium sulfate (AS) to precip-
itate and concentrate rAAV1.11 Therefore, we ﬁrst tested whether AS
can be used to precipitate rAAV9. To test AS precipitation, rAAV9
(AAV9-double-stranded EGFP [dsEGFP], using pdsAAV-chicken
b-actin [CBA]-EGFP) was produced by HEK293 cells (Materials
and Methods). Figure 1 shows that a two-step precipitation proced-
ure using sequential 1/3- and 1/2-saturated AS treatments (1/3/1/2
AS, lane 5) yielded better purity than a one-step procedure using
only the 1/2-saturated AS treatment (1/2 AS, lane 3). Viral purity
was determined by SDS-PAGE. The total protein amount following
1/3/1/2 AS treatment was 11% less than 1/2 AS treatment, as
determined by densitometry of protein band intensities using ImageJ
software. Many low-molecular-weight proteins were removed by
1/3/1/2 AS treatment (Figure 1, lanes 3–5). Thus, the AS treatment
we describe is a viable method for rAAV9 precipitation.Purification of AAV9-dsEGFP by Quaternary Ammonium Anion
Exchangers and Size-Exclusion Chromatography
Next we used a chromatographic technique for laboratory-scale pro-
duction of highly pure rAAV9. To increase the rAAV9 yield, we
chose the HEK293EB cells, which express the E1 gene region (E1A,
E1B19K, and E2A) and the BCL-XL gene; these cells yield 2-fold
more rAAV than HEK293 cells.24 For the laboratory-scale puriﬁca-
tion, AAV9-dsEGFP was produced using 3.2  109 HEK293EB cells
(the volume of medium was 1,120 mL). After 1/3/1/2 AS treatment,
the AAV9-dsEGFP sample was dissolved in 20 mL of 3.3 mM mor-
pholinoethanesulfonic acid, 3.3 mM 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid, and 3.3 mM sodium acetate buffer (MHN
buffer, dilution buffer; pH 8.0) containing 50 mM NaCl and 0.01%
(w/v) Pluronic F-68. This puriﬁcation method was based on the
results of a preliminary small-scale experiment (Supplemental Mate-
rials and Methods; Figure S1). The 1/3/1/2 AS treatment was appli-
cable to rAAV9 produced from HEK293EB cells. The 1/3/1/2 AS-
treated crude AAV9-dsEGFP fraction was diluted in dilution buffer
until the conductivity of the solution decreased to 7.3 mS/cm. A
HiPrep Q XL 16/10 column with a bed volume of 20 mL was used
for laboratory-scale puriﬁcation. This column has the same speciﬁca-
tions as the HiTrap Q FF column with a bed volume of 1 mL used for
preliminary small-scale experiments. The diluted sample was loaded
onto the HiPrep Q XL 16/10 column equilibrated with dilution buffer
at a rate of 3 mL/min, achieved by a peristaltic pump P1. Figure 2A
shows the three major protein bands present in the pass-through
fraction (lane 6) and the protein impurities retained in the col-
umn-bound fraction (lane 8), consistent with the results of the pre-
liminary small-scale experiment (using HiTrap Q FF; Figure S1).
The 200-kDa impurity (white arrowhead in Figure 2A), which was
difﬁcult to remove during rAAV1 puriﬁcation, was separated from
the rAAV9 preparation just by loading onto the anion-exchange
column. The pass-through fraction was concentrated using an
Ultracel 30 K centrifugal ﬁlter unit. Finally, AAV9-dsEGFP was pu-
riﬁed by size-exclusion chromatography (HiLoad 16/60 Superdexrapy: Methods & Clinical Development Vol. 11 December 2018 181
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Figure 2. Laboratory-Scale Purification of AAV9-dsEGFP by Quaternary Ammonium Anion-Exchange Column and Size-Exclusion Chromatography
(A) The AAV9-dsEGFP preparations were analyzed by 5%–20% (v/v) gradient gel SDS-PAGE and stained with Oriole fluorescent gel stain before and after chromatography
purification using a HiPrep Q XL 16/10 column. The white arrowhead indicates a 200-kDa impurity. Lane 1, pre-TFF; lane 2, post-TFF; lane 3, after heat treatment; lane 4,
1/3/1/2 AS; lane 5, diluted 1/3/1/2 AS; lane 6, pass-through fraction; lane 7, wash-out fraction; lane 8, column-bound and eluted fraction. (B) The pass-through fraction
was subsequently subjected to size-exclusion chromatography using a HiLoad 16/60 Superdex 200 preparation-grade column using an A¨KTA Explorer 100 HPLC system
equipped with a 10-mL sample loop, with MHN buffer (pH 6.5) containing 300 mM NaCl and 0.01% (w/v) Pluronic F-68 as the mobile phase. y axis, 280 nm absorbance;
x axis, fraction number. The black arrowhead indicates the peak fractions of the rAAV9 (corresponding to lanes 2–14 in C). (C) The elution fraction was analyzed by two
5%–20% (v/v) gradient SDS-PAGE gels with Oriole fluorescent staining; the left gel is from lanes 1–12, and the right gel is from lanes 13–23. Lanes 1–18, fractions 14–31;
lane 19, fraction 33; lane 20, fraction 35; lane 21, fraction 37; lane 22, fraction 39; lane 23, fraction 41. Peak fractions (fractions 15–27) were collected to obtain the final
product. (D–G) The final AAV9-dsEGFP product was analyzed by 5%–20% (v/v) gradient gel SDS-PAGE with Oriole fluorescent staining (D), western blotting (E, anti-AAV
capsid monoclonal antibody B1), EM (F, negative staining), and analytical ultracentrifugation (AUC, G). Shown are the peak fractions of (i) empty particles (68.6 S, 25.7%),
(ii) intermediate particles (88.8 S, 32.4%), and (iii) fully packaged virions (102.6 S, 38.8%). The goodness of fit (RMSD) was 0.004635. y axis, continuous-size C(S) distribution;
x axis, sedimentation coefficient. Lane 1 and lane 2, the final rAAV9 product. The three bands represent the AAV9 capsid proteins VP1 (82 kDa), VP2 (67 kDa), and
VP3 (60 kDa).
Molecular Therapy: Methods & Clinical Development200, preparation-grade) using an ÄKTA Explorer 100 high perfor-
mance liquid chromatography (HPLC) system equipped with a
10-mL sample loop and MHN (pH 6.5) buffer containing 300 mM182 Molecular Therapy: Methods & Clinical Development Vol. 11 DecemNaCl and 0.01% (w/v) Pluronic F-68. The peak indicated by a black
arrowhead in the chromatogram (Figure 2B) and the protein bands
in lanes 2–14 (Figure 2C) represent the rAAV9 particles. Peakber 2018
Table 1. Total Titer at Each Step (Pre-TFF, Post-TFF, Anion-Exchange Column Purification, and Final Product) and Recovery, Measured by qPCR, in Five
Trials (Three Trials for AAV9-dsEGFP, One Trial for AAV9-dsLuc, and One Trial for AAV-ssLuc)
rAAV Genome dsAAV-CBA-EGFP dsAAV-CBA-RFLuc ssAAV-CMV-RFLuca
AAV genome form ds ds ss
GC content 59% 55% 52%
Trial number 1 2 3 4 5
Total Titer
Pre-TFFb,c 1.3  1016 v.g. 9.9  1015 v.g. 1.0  1016 v.g. 8.5  1015 v.g. 3.6  1014 v.g.
Post-TFFc 5.3  1015 v.g. 5.2  1015 v.g. 4.1  1015 v.g. 7.0  1015 v.g. 2.9  1014 v.g.
Anion-exchange column puriﬁcationc 3.2  1015 v.g. 3.3  1015 v.g. 2.1  1015 v.g. 4.9  1015 v.g. 2.0  1014 v.g.
Final productc,d 2.9  1015 v.g. 2.7  1015 v.g. 2.0  1015 v.g. 3.9  1015 v.g. 1.8  1014 v.g.
Final producte 3.7  1014 v.g. 4.3  1014 v.g. 3.0  1014 v.g. 4.0  1014 v.g. 8.7  1013 v.g.
Recoveryf 60% 63% 51% 70% 69%
Total recoveryg 22% 27% 20% 46% 50%
Empty capsids (empty capsids/total particles) 3.8% (195/5,168) 5.2% (230/4,404) 2.6% (79/3,013) 7.3% (343/4,684) 3.8% (211/5,561)
Contaminating empty capsids in the ﬁnal product were determined by EM.
aThe standard plasmid used for qPCR was different from the one used for dsAAV measurement as described in Materials and Methods.
bThe initial volume of medium was 1,120 mL.
cThe titers were measured using ITR-targeted primers.
dThe volume of ﬁnal product was 13 mL.
eThe titers were measured using non-ITR-targeted primers.
fThe recovery was calculated by dividing the titer of “anion-exchange column puriﬁcation” by the titer of “post-TFF.”
gTotal recovery was calculated by dividing the titer of “ﬁnal product measured using ITR-targeted primers” by the titer of “pre-TFF.”
www.moleculartherapy.orgfractions (fractions 15–27) were collected to obtain the ﬁnal product.
The resultant total titer of pure AAV9-dsEGFP was 2.9 1015 v.g. or
3.7  1014 vector genomes (v.g.), measured by qPCR using primers
targeting the inverted terminal repeats (ITR) or EGFP, and the ﬁnal
product contained 3.8% (195 of 5,168 particles) of empty capsids, as
determined by negative-stain electron microscopy (EM) (trial 1,
Table 1). According to Figure S2, a certain level of empty capsids
was observed in the diluted sample just before loading onto the
anion-exchange column; thus, use of the anion-exchange column
was enough to remove the empty particles. Taken together, our chro-
matographic procedure enables puriﬁcation of high-quality rAAV9.
Qualification of the Final AAV9-dsEGFP Preparation
To assess reproducibility, AAV9-dsEGFP puriﬁcation was replicated
three times (Figure 2; Figure S3). The ﬁnal products contained the
three major highly pure protein bands that represent the AAV9
capsid proteins, VP1 (82 kDa), VP2 (67 kDa), and VP3 (60 kDa).
The total capsid protein (VP1+VP2+VP3) pixel intensity was
94.9% ± 1.1% (n = 3), as determined by ImageJ densitometry of the
SDS-PAGE gradient gels stained with Oriole ﬂuorescent gel stain,
and the capsid proteins derived from rAAV9 were determined by
gels immunoblotted with the monoclonal antibody B1 (Figures 2D
and 2E; Figures S3A, S3B, S3D, and S3E). Of the puriﬁed AAV9-
dsEGFP particles, 96.1% ± 1.1% (n = 3) contained the viral genome,
as determined by negative-stain EM (Figure 2F; Figures S3C and S3F).
We also assessed the puriﬁed AAV9-dsEGFP with analytical ultracen-
trifugation (AUC) (Figure 2G). Unlike the EM result, it suggested that
the ﬁnal product contained approximately 26% of empty particles.Molecular TheThe resultant total titer was 2.5 ± 0.4  1015 v.g., as measured using
ITR-targeted primers (n = 3) (Table 1), or 3.7 ± 0.7  1014 v.g., as
measured by EGFP-targeted primers. To assess the removal of human
genomic DNA contamination likely derived from HEK293EB cells,
we analyzed the ﬁnal puriﬁed rAAV9 preparation by qPCR using
human glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
primers (Table 2). No copy of human GAPDH (detection limit of
one copy of human GAPDH) was detected in the ﬁnal product (con-
taining 1.0 109 v.g.) and in the solvent of the ﬁnal product; however,
2.6 copies of human GAPDH were detected in the post-tangential
ﬂow-ﬁltration (post-TFF) solvent (containing 1.0  109 v.g.). There-
fore, human genomic DNA contamination can be removed with the
chromatographic puriﬁcation process described here. Furthermore,
we evaluated the efﬁciency of the puriﬁed AAV9-dsEGFP to trans-
duce HEK293EB cells (Table 3). The three puriﬁed replicates did
not signiﬁcantly differ in terms of transduction efﬁciency. Altogether,
our protocol achieves reproducible puriﬁcation of infectious AAV9-
dsEGFP.
Application Scope and Reliability
To examine whether our puriﬁcation protocol could be applied to
different AAV constructs, we puriﬁed rAAV9 with dsAAV-CBA-
red ﬁreﬂy luciferase (AAV9-dsLuc) and single-stranded AAV-
CMV-RFLuc (AAV9-ssLuc) transgenes. The same puriﬁcation
procedure as used to purify AAV9-dsEGFP was performed. AAV9-
dsLuc and AAV9-ssLuc preparations are shown in Figures 3A–3C
and Figures 3D–3F, respectively. The ﬁnal products contained the
three major highly pure protein bands representing the AAV9 capsidrapy: Methods & Clinical Development Vol. 11 December 2018 183
Table 3. The Proportion of EGFP-Positive HEK293EB Cells and Intensity of
EGFP Fluorescence in Cells Transduced with Final rAAV9
Sample (v.g./cell) 5  106
Trial 1 2 3
EGFP-positive 11.3% 10.0% 10.4%
No signiﬁcant difference was observed among the three preparations by one-way
ANOVA; p = 0.343. The signiﬁcance threshold was set at 0.05.
Table 2. Levels of Contaminating Human Genomic DNA Quantified in the
Final Preparation of AAV9-dsEGFP
rAAV9 (1.0  109 v.g.)
Human Genomic DNA
Contamination
Benzonase Treatment Final Producta Post-TFF
+b <1 copyc <1 copyc
d <1 copyc 2.6 copies
aFinal products of three trials (AAV9-dsEGFP) were examined.
bBenzonase treatment (+) represents the contaminating human genomic DNA in
rAAV9 particles.
cLess than one copy means below the detection limit.
dBenzonase treatment () represents the contaminating human genomic DNA in and
outside of rAAV9 particles.
Molecular Therapy: Methods & Clinical Developmentproteins, as observed by SDS-PAGE and western blotting (Figures 3A,
3B, 3D, and 3E). The total capsid protein (VP1+VP2+VP3) intensity
was 84% for AAV9-dsLuc and 86% for AAV9-ssLuc, as determined
by densitometry using ImageJ. Of the puriﬁed rAAV9 particles,
92.7% (4,341 of 4,684 particles) of AAV9-dsLuc and 96.2% (5,350
of 5,561 particles) of AAV9-ssLuc contained the viral genomes
(Figures 3C and 3F). The resultant titer of pure AAV9-dsLuc was
3.9  1015 v.g., as measured using ITR-targeted primers (4.0  1014
v.g., as measured by Luc-targeted primers), and that of pure AAV9-
ssLuc was 1.8  1014 v.g., as measured using ITR-targeted primers
(8.7  1013 v.g., as measured by Luc-targeted primers) (Table 1).
Thus, we conclude that our puriﬁcation procedure was also applicable
for ssAAV and dsAAV of different transgenes. The procedures
for rAAV9 production and puriﬁcation used in our study are sche-
matically shown in Figure 4. Three plasmids were transfected into
HEK293EB cells using polyethyleneimine; cells were maintained in
DMEM without serum. Five days later, the culture supernatant was
collected and ultraﬁltrated using TFF. The ultraﬁltrated sample was
precipitated by 1/3/1/2 AS treatment. Subsequently, the sample
was puriﬁed by quaternary ammonium anion exchanger. The column
resin retained the impurities and empty capsids; puriﬁcation of the
pass-through fraction containing rAAV9 was performed using size-
exclusion chromatography.
DISCUSSION
We recently developed an efﬁcient protocol for rAAV1 preparation
using chromatographic puriﬁcation and excluding ultracentrifuga-
tion.11 In this study, we attempted to optimize this procedure for
purifying rAAV9 preparations. rAAV9 could be crudely puriﬁed by
precipitation using saturated ammonium sulfate (1/3/1/2 AS), the
same as rAAV111 (Figure 1). During rAAV1 puriﬁcation, rAAV1
and a 200-kDa impurity were bound to the anion-exchange column,
but the 200-kDa impurity was separated from the ﬁnal product by
stepwise NaCl gradient elution. The 200-kDa impurity was also
observed during the rAAV9 puriﬁcation steps (white arrowhead in
Figure 2A, lanes 1–5). In contrast to rAAV1 puriﬁcation, this impu-
rity bound to the anion- exchange column, whereas rAAV9 passed
through the column; thus, this impurity was removed just by using
the anion-exchange column (Figure 2A). Consistent with our results,
Zhou et al.25 also reported that efﬁcient binding of rAAV9 to either184 Molecular Therapy: Methods & Clinical Development Vol. 11 Decemanion-exchange or cation-exchange resin was difﬁcult. These results
indicated that rAAV9 adsorption onto the anion exchanger markedly
differed from that of rAAV1 during puriﬁcation. A possible factor
affecting rAAV adsorption onto the anion-exchange column may
be the rAAV’s isoelectric point (pI). Venkatakrishnan et al.26 revealed
that the unique N-terminal domain of VP1 undergoes a pH-induced,
reversible change of folding that results in the loss or gain of its
a-helical structure, does not disrupt capsid integrity, and is likely
facilitated by changes in its pI. However, they also reported that no
signiﬁcant difference in pI was observed between AAV1 and
AAV9. Moreover, both rAAV1 and rAAV9 were dissolved in a buffer
at pH8.0 during our puriﬁcation procedure. Thus, pI seems unlikely
to be the critical determinant of the difference in rAAV1 and rAAV9
adsorption onto the anion exchanger. Small differences in amino acid
side chains exposed on the rAAV surface may potentially contribute
to its adsorption onto the anion-exchange column. Interestingly,
AAV2.5, which was generated using the AAV2 capsid by substituting
only ﬁve residues of AAV1, is distinct from AAV2 in terms of capsid
characteristics.27 Although AAV1 shares 84.6% of capsid amino acid
sequence identity with AAV9, a difference of several residues may
affect the surface charge, leading to differences in rAAV1 and
rAAV9 puriﬁcation methods using ion-exchange chromatography.
rAAV9 puriﬁcation has been reported previously.17,25,28 Lock et al.17
puriﬁed rAAV9 from culture supernatants using iodixanol gradient
ultracentrifugation. The rAAV9 product was highly pure, and the
genomic titer was comparable with our ﬁnal rAAV9 preparation;
however, an 4.7 times larger cell growth area than in our protocol
was used to produce rAAV9. Zhou et al.25 reported that rAAV9
extracted from cell lysates did not bind efﬁciently onto the anion-
exchange column under low-salt loading conditions (25 mM NaCl)
at pH 8.5. Therefore, both ceramic hydroxyapatite chromatography
and cation-exchange (Poros 50HS) chromatography were subse-
quently performed in the presence of polyethylene glycol. However,
the ﬁnal rAAV9 preparation was contaminated with 30% of empty
capsids; thus, CsCl ultracentrifugation was used to remove the empty
capsids for in vivo transduction experiments. Potter et al.28 puriﬁed
rAAV9 from cell lysates by cation-exchange chromatography at a
lower pH (pH 3.9), but their method also resulted in a highly contam-
inated ﬁnal preparation containing empty capsids, according to their
EM analysis. Other methods of afﬁnity chromatography for rAAV9
puriﬁcation have also been reported.29,30 An afﬁnity resin derivatized
with single-domain monospeciﬁc antibody fragments against AAV9
capsids (Poros Capture Select AAV9) is available. Nass et al.31ber 2018
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Figure 3. Laboratory-Scale Purification of AAV9-
dsLuc or AAV9-ssLuc
(A–F) Purity assessment of (A–C) AAV9-dsLuc and (D–F)
AAV9-ssLuc. The preparation of final rAAV9 product was
analyzed by (A and D) 5%–20% (v/v) gradient gel SDS-
PAGE with Oriole fluorescent staining, (B and E) western
blotting, and (C and F) EM (negative staining). Lane 1 and
lane 2, final purified rAAV9 product. The three bands
represent the AAV9 capsid proteins VP1 (82 kDa), VP2
(67 kDa), and VP3 (60 kDa).
www.moleculartherapy.orgdemonstrated that the empty capsids and fully packaged virions were
bound to the column under neutral pH conditions, and fully pack-
aged rAAV9 was 11%, whereas the empty capsids were 88%, eluted
by acidic conditions of pH 3.0–2.0. The acidic solution may be able
to reduce the infectivity of rAAVs, and additional puriﬁcation steps
are required to separate the empty capsids from rAAV particles.
Furthermore, this resin is too expensive to promote gene therapy
by rAAV9 more widely ($2,735 for 25 mL). In contrast to previous
reports, our successful puriﬁcation is a signiﬁcant methodological
advancement. The ﬁrst advantage of our protocol is the simplicity
of the puriﬁcation steps. Simple puriﬁcation using anion-exchange
and size-exclusion chromatography sufﬁciently remove most cellular
contaminants and empty capsids from rAAV particles. This elimi-
nates the laborious puriﬁcation steps and multiple ion-exchange col-
umns. Second, our protocol provides a ﬁnal rAAV9 preparation of
high quality and high yield despite its simplicity. The total titer of
the ﬁnal rAAV9 product in our protocol was 2.5 ± 0.4  1015 v.g.,Molecular Therapy: Methods & Clinas measured using ITR-targeted primers (3.7 ±
0.7 1014 v.g., as measured using EGFP-targeted
primers), which is comparable with or higher
than that obtained using other protocols. In our
ﬁnal preparations, 96.1% ± 1.1% of the particles
contained the viral genome, according to our
negative-stain EM analysis (Figure 2F; Figures
S3C and S3F). We also assessed the ﬁnal
AAV9-dsEGFP with AUC and observed about
38.8% of fully packaged virions and 25.7% of
empty capsids in our ﬁnal preparations (Fig-
ure 2G). Burnham et al.32 reported that fully
packaged rAAV9 harboring a 2,050-nt genome
were 34.4% ± 0.7% of the total in the ﬁnal prep-
aration (n = 5). Even though this is only a basic
comparison of these values and our results, we
believe that our simple puriﬁcation method is
reasonably similar. A method to evaluate the dif-
ference between EM and AUC and to identify the
approximately 30% of intermediated particles
(fragmented virus genome containing virions) is
unclear at this moment. The full particles deter-
mined by EM may not be the veritable full parti-
cles when measured by AUC. Although EM has
been conventionally used for evaluating theempty particle/full particle ratio, we may need to assess quality using
both EM and AUC in the future. To achieve that, it is important to
accumulate much data comparing EM and AUC moving forward.
Third, our puriﬁcation protocol can be used regardless of the type
of AAV genome constructs (i.e., ss or ds, genome size, and GC con-
tent) (Figure 3; Table 1). Taken together, the procedures we describe
here are fast, convenient, and versatile and efﬁciently remove empty
capsids, producing high yields of highly pure rAAV9 for potential
clinical use.
Contaminating empty capsids in the ﬁnal rAAV preparations often
compete for cell surface receptors and, consequently, prevent efﬁcient
transduction33 and can induce immune responses.34 To avoid this,
empty particles must be cleared.We speculate that, in our puriﬁcation
steps, empty particles were initially removed by AS treatment.
Although the starting material, a non-puriﬁed sample, contains
many empty particles,35 the AS-treated sample contained fewerical Development Vol. 11 December 2018 185
Figure 4. Schematic Representation of rAAV9 Production and Purification
HEK293EB cells were transfected with three plasmids (cis AAV vector plasmid,
trans plasmid, and helper plasmid) using polyethyleneimine (PEI, Polyethyleneimine
Max) and maintained in DMEM without serum. After collecting the culture super-
natant, it was ultrafiltrated by TFF with a hollow fiber using the KrosFlo Research
Ili system. After reducing the amount of protein debris by 1/3-saturated AS
precipitation, rAAV9 was precipitated in 1/2-saturated AS solution (1/3/1/2 AS).
The precipitated rAAV fraction was loaded onto a quaternary ammonium anion-
exchange column. The pass-through fraction was finally purified by size-exclusion
chromatography.
Molecular Therapy: Methods & Clinical Developmentempty particles (Figure S2). We predict that the difference in surface
structure between full particles and empty particles inﬂuences the
hydrophobic interaction with AS; as a result, a certain level of empty
particles was removed by AS treatment. Furthermore, we previously
demonstrated efﬁcient puriﬁcation procedures to eliminate the
contaminating empty capsids from rAAV1 and rAAV8 prepara-
tions.10,11 We also demonstrated that the pI differed according to
the presence or absence of the viral genome in AAV particles.10 Using
similar strategies, many others have also developed procedures for
efﬁciently separating the empty capsids from packaged rAAV parti-
cles based on pI differences using ion-exchange chromatog-
raphy.10,11,15,36–38 Qu et al.36 successfully removed AAV2 empty cap-
sids using an cation-exchange resin, POROS 50HS, followed by an
anion-exchange resin, Q-Sepharosexl. Using this method, they could
obtain rAAV2 preparations that contained less than 20% of empty
capsids of the total particles. Lock et al.37 separated empty capsids
from rAAV8 particles by charge using a monolithic anion-exchange
column, CIM-QA disk. They also successfully obtained rAAV8 par-
ticles containing 6.3% of empty capsids. In many procedures, rAAV
particles were bound to ion exchangers ﬁrst, and rAAV particles
were separated from impurities or empty capsids by subsequent, step-186 Molecular Therapy: Methods & Clinical Development Vol. 11 Decemwise gradient elution, similar to our rAAV1 puriﬁcation.11 Contrary
to other serotypes, rAAV9 particles are unlikely to bind efﬁciently to
an anion exchanger under common conditions. Taking advantage of
this rAAV9 characteristic, we successfully removed empty capsids
from ﬁnal rAAV9 products by passing them through the anion-
exchange column. Although the mechanisms underlying this
rAAV9 characteristic remain unknown, our results provide novel in-
sights into establishing efﬁcient puriﬁcation strategies for removing
the empty capsids derived from other natural or synthetic serotypes.
In consideration of the AUC result, another chromatography step
may be needed to further remove empty particles following the
anion-exchange column to remove impurities and some empty
particles.
Although our procedure can be successfully applied to laboratory-
scale rAAV9 puriﬁcation, it can also be applied to large-scale
rAAV9 puriﬁcation. For example, Grieger et al.38 reported that func-
tional rAAVs could be obtained from suspended cells grown in
animal component-free medium. In combination with their suspen-
sion and xeno-free culture system, our puriﬁcation method will be
easily scalable and adapted for current good manufacturing practice.
In addition, our ultracentrifugation-free and CsCl-free procedure
minimizes the risk of acute toxicity. Therefore, our streamlined,
scalable, high-performance anion-exchange and size-exclusion chro-
matography protocols should facilitate future clinical studies using
puriﬁed rAAV9.
MATERIALS AND METHODS
Cell Culture
HEK293 or HEK293EB cells (HEK293 cells stably expressing the E1
gene region and the BCL-XL gene) were cultured at 37C in a 5%
CO2 atmosphere inDMEM(Sigma-Aldrich, St. Louis,MO) containing
8% (v/v) fetal bovine serum (FBS) (Biowest, Nuaillé, France) and peni-
cillin and streptomycin (Sigma-Aldrich, St. Louis, MO). HEK293 cells
were used for optimization of AS treatment conditions and in small-
scale experiments. In laboratory-scale experiments, HEK293EB cells
(3.2  109 cells in total) were plated in 16 square culture dishes
(245 245 18mm; 500 cm2; Corning, NewYork, NY)with a surface
area totaling 8,000 cm2. The initial volume of medium was 1,120 mL.
Plasmids
The three cis AAV vector plasmids used were pdsAAV-CBA-EGFP,
pdsAAV-CBA-RFLuc, and pssAAV-CMV-RFLuc. The pdsAAV-
CBA-EGFP expresses the EGFP gene under the control of the CBA
promoter with AAV type 2 ITR (donated byDr. Arun Srivastava, Uni-
versity of Florida). In pdsAAV-CBA-RFLuc, the red ﬁreﬂy luciferase
(RFLuc) fragment was ampliﬁed by PCR using the pCMV-RedFluc
plasmid (Targeting Systems, El Cajon, CA) as a template and using
the primers 50-AACGAATTCGGATCCGCCACCATGGAAACAGA
AAGAGAAGAAAACG-30 and 50-CTGGAATTCAAGCTTCTACC
CACCTGCTTGAGGTTTCTTG-30; the resultant PCR product was
digested using NcoI and HindIII, and it was used to replace the
EGFP in pdsAAV-CBA-EGFP. In pssAAV-CMV-RFLuc, the RFLuc
fragment was ampliﬁed by PCR as described above and cloned intober 2018
www.moleculartherapy.orgthe EcoRI-HindIII site of pAAV-MCS (Agilent Technologies). The
trans plasmid, pAAV2/9 (with the AAV type 2 rep gene and type 9
cap gene), was donated by JamesM.Wilson (University of Pennsylva-
nia). The adenovirus helper plasmid, pHelper (with an essential region
from the adenovirus genome), was purchased from Stratagene (La
Jolla, CA).
Production of rAAV9 and Preparation of the Crude rAAV9
Fraction
HEK293 or HEK293EB cells were grown for 2 days to reach 90%
conﬂuence. The cis, trans, and adenovirus helper plasmids were trans-
fected at a ratio of 1:1:239,40 (44.8 mg of cis plasmid, 44.8 mg of trans
plasmid, and 90.1 mg of pHelper per square dish) to cells maintained
in DMEM without serum supplemented with GlutaMAX-_ (Gibco,
Life Technologies) and using polyethyleneimine (PEIMax, Polyscien-
ces, Warrington, PA) at a DNA:PEI ratio of 1:2.17 The culture super-
natant was collected 120 h after transfection, ﬁltrated through a
0.45-mm ﬁlter (Thermo Fisher Scientiﬁc, Waltham, MA), and ultraﬁl-
trated by TFF using a hollow ﬁber cartridge (UFP-750-E-3MA;
750,000 nominal molecular weight cutoff; GE Healthcare, Westbor-
ough, MA) using the KrosFlo Research Ili TFF system (Spectrum Lab-
oratories, Rancho Dominguez, CA). Subsequently, the crude rAAV9
fraction was treated with 25 U/mL benzonase (Novagen, San Diego,
CA) for 30 min at 37C. The reaction was terminated by adding
0.5 M ethylenediaminetetraacetic acid. The crude rAAV9 fraction
was heated for 20 min at 50C to denature the low-molecular-weight
proteins. The denatured proteins were removed by three cycles of
centrifugation at 13,100  g for 10 min each. Next, 1/3 AS precipita-
tion was performed by adding half of the sample volume of saturated
AS to produce a ﬁnal solution of 33% (w/v) AS, followed by centrifu-
gation at 18,800 g for 30min at 4C. rAAV9 was ﬁnally precipitated
in 1/2 AS solution (by adding half of the original sample volume of
saturated AS) (1/3/1/2 AS), followed by centrifugation at
18,800  g for 30 min 4C. The precipitated rAAV9 was dissolved
in 20 mL of a buffer containing 3.3 mM morpholinoethanesulfonic
acid (Dojindo, Kumamoto, Japan), 3.3 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (Dojindo), and 3.3 mM sodium acetate
(Sigma-Aldrich, St. Louis, MO) (MHN buffer), pH 8.0, for labora-
tory-scale puriﬁcation using a HiPrep Q XL 16/10 column (GE
Healthcare, Uppsala, Sweden). The MHN buffer contained 50 mM
NaCl and 0.01% (w/v) non-ionic surfactant Pluronic F-68 (Sigma-
Aldrich).
Purification of rAAV9 by Quaternary Ammonium Anion
Exchangers and Size-Exclusion Chromatography
For laboratory-scale puriﬁcation, 20 mL of 1/3/1/2 AS-treated sam-
ple was dissolved and diluted in MHN buffer until the conductivity of
the solution decreased to 7.3 millisiemens/cm. The conductivity
was measured using an electroconductivity sensor (LAQUAtwin,
HORIBA, Tokyo, Japan). The diluted sample was loaded onto a
quaternary ammonium anion exchanger with a bed volume of
20 mL (HiPrep Q XL 16/10) equilibrated with each buffered solution
at a rate of 3 mL/min and controlled by a P1 peristaltic pump (Pump
P1, GE Healthcare). The pass-through fraction was collected andMolecular Theultraﬁltrated using Ultracel 30 K centrifugal ﬁlters (Merck Millipore,
Billerica, MA). We also collected the sample washed out through the
anion-exchange column and the sample eluted from the anion-
exchange column using MHN buffer (pH 8.0) containing 1 M NaCl
and 0.01% (w/v) Pluronic F-68. The pass-through fraction was puri-
ﬁed by size-exclusion (gel ﬁltration) chromatography using a HiLoad
16/60 Superdex 200 preparation-grade column (GE Healthcare) and
an ÄKTA Explorer 100 HPLC system (GE Healthcare) equipped with
a 10-mL sample loop running the MHN buffer (pH 6.5) containing
300 mM NaCl and 0.01% (w/v) Pluronic F-68. Fractions were
collected as follows: ﬁrst segment, 0.2 column volume (CV), 5-mL
fractions; second segment, 0.6 CV, 1-mL fractions; third segment,
0.3 CV, 5-mL fractions (1 CV = 120 mL). Peak fractions (fractions
15–27) were collected to obtain the ﬁnal product. The purity of the
ﬁnal rAAV9 product was assessed by 5%–20% (v/v) gradient gel
SDS-PAGE (SuperSep Ace, 5%–20%, 13-well, Wako, Osaka, Japan)
and protein staining with either Quick Coomassie brilliant blue (Q-
CBB, Wako, Osaka, Japan) or Oriole ﬂuorescent gel stain (Bio-Rad,
Hercules, CA) and by western blotting using an anti-AAV-capsid
monoclonal antibody (B1, Progen, Heidelberg, Germany).
qPCR
For puriﬁcation of rAAV viral DNA, puriﬁed rAAV9 was treated with
125 U/mL benzonase and 2 mMMgCl2 for 30 min at 37C. The viral
genome DNA was extracted using the DNeasy Blood & Tissue
Kit (QIAGEN, Hilden, Germany). The benzonase-resistant genome
titer was measured by real-time qPCR (7500 Fast Real-Time PCR Sys-
tem, Applied Biosystems, Foster City, CA) using ITR-targeted primers
(forward primer, 5ʹ-GGAACCCCTAGTGATGGAGTT-3ʹ; reverse
primer, 5ʹ-CGGCCTCAGTGAGCGA-3ʹ),41 EGFP-targeted primers
(forward primer, 50-AGCAGCACGACTTCTTCAAGTCC-30; reverse
primer, 50- TGTAGTTGTACTCCAGCTTGTGCC-30), or RFLuc-
targeted primers (forward primer, 50- TCGACATCAGCTACCAG
CAG-30; reverse primer, 50-ATCCCCAGACTGTGGTTCAG-30) and
SYBR green dye (SYBR Premix DimerEraser [Perfect Real Time] or
TB Green Premix EX Taq II [Tli RNase H Plus], TaKaRa, Japan).
The qPCR conditions were 10 s at 95C, followed by 40 cycles at
95C for 5 s and 60C for 34 s. Linearized pdsAAV-CBA-EGFP
DNA (digested by SacI restriction enzyme), pdsAAV-CBA-RFLuc
DNA (digested by XmnI restriction enzyme), or pssAAV-CMV-
RFLuc DNA (digested by BamHI restriction enzyme) were used as
standard plasmids for rAAV9 with dsDNA or rAAV9 with ssDNA,
respectively. The standard plasmids were puriﬁed with the QlAquick
Gel Extraction Kit (QIAGEN).
SDS-PAGE and Western Blot Analyses
The puriﬁed rAAV9 preparation was separated by 5%–20% (v/v)
gradient polyacrylamide gel (Wako) in a running buffer containing
SDS. To visualize and analyze the SDS-PAGE bands during AS treat-
ment condition optimization and small-scale experiments, we used
Q-CBB (Wako), and for the rest of the experiments we used Oriole
ﬂuorescent gel stain (Bio-Rad). The sensitivity of the Oriole gel stain
is almost equal to that of silver staining.42 For western blotting,
samples were transferred overnight onto polyvinylidene ﬂuoriderapy: Methods & Clinical Development Vol. 11 December 2018 187
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blocked in 3% (w/v) BSA in Tris-buffered saline containing 0.05%
(v/v) Tween 20 (TBST) and incubated with the primary antibody
(1:1,000, monoclonal antibody B1, Progen, Heidelberg, Germany)
for 1 hr at 4C. After rinsing three times in TBST, the membranes
were incubated with a horseradish peroxidase-labeled secondary
anti-mouse antibody (1:10,000, GE Healthcare) for 1 hr at 4C.
Then the membranes were washed three times in TBST. The protein
was detected using the enhanced chemiluminescence (ECL) Plus
Western Blotting Detection System (GE Healthcare).
Measurement of Contaminating Human Genomic DNA
Contamination
Contaminating human genomic DNA in ﬁnal preparations
(AAV9-dsEGFP, three trials) was quantiﬁed by qPCR using human
GAPDH-targeting primers (forward primer, 5ʹ-CTGGGCTACA
CTGAGCACC-3ʹ; reverse primer, 5ʹ-AAGTGGTCGTTGAGGG
CAATG-3ʹ; NCBI: Pr032064752)43 and SYBR green dye (SYBR
Premix DimerEraser [Perfect Real Time]). Human genomic DNA
(Roche, Mannheim, Germany) was used as a standard DNA. For
detection of contaminating human genomic DNA in rAAV9 parti-
cles, samples were treated with 125 U/mL benzonase and 2 mM
MgCl2, and then the viral DNA was puriﬁed with the DNeasy
Blood & Tissue Kit. For detection of contaminating human
genomic DNA outside of rAAV9 particles, the viral DNA was
analyzed without benzonase treatment. The qPCR conditions
were 10 s at 95C, followed by 40 cycles of 95C for 5 s and
60C for 34 s.
Measurement of the Transduction Efficiency of the Purified
AAV9-dsEGFP
Triplicate wells containing 4.7  105 HEK293EB cells were infected
with puriﬁed AAV9-dsEGFP at 5.0  106 v.g./cell. Three days after
transduction, the proportion of EGFP-positive cells was measured
by ﬂow cytometry (FACSCantoII, Becton Dickinson, Franklin Lakes,
NJ) with propidium iodide staining (Immunostep, Salamanca, Spain)
to identify and exclude nonviable cells. Signiﬁcant differences were
determined using ANOVA by Microsoft Excel.
Electron Microscopy
A carbon-stabilized copper grid (Nisshin EM, Tokyo, Japan) was
placed onto a test sample and incubated for 1 min. The sample on
the grid was then negatively stained for 1 min with 1% (w/v) uranyl
acetate. Finally, the grid was examined using a H-7650 transmission
electron microscope (Hitachi, Tokyo, Japan) at an accelerating
voltage of 80 kV. The ratio of empty particles to encapsulated particles
was determined by counting the number of packaged and unpackaged
particles in the electron micrographs.
AUC
Sedimentation velocity AUC analysis was conducted with a Proteome
Lab XL-1 ultracentrifuge (Beckman Coulter, Indianapolis, IN). Four
hundred microliters of AAV9-dsEGFP was loaded into the sample
compartment of the centerpiece, and 400 ml of solvent was loaded188 Molecular Therapy: Methods & Clinical Development Vol. 11 Deceminto the reference compartment of the centerpiece. The four-hole
rotor loaded the sample in the instrument, and it was equilibrated
to a temperature of 20C. Sedimentation velocity centrifugation was
performed at 12,000 rpm and 20C, and absorbance (260 nm) was
used for analysis.
AUC Data Analysis
The percentages of fully packaged virions, intermediate particles, and
empty particles were determined by analyzing 92 scans and the Sedﬁt
continuous-size C(S) distribution model. The following C(S) param-
eters were used for analysis: resolution, 100 S; S min, 20; S max, 120;
frictional ration, 1.32859; F statistic, 0.68; buffer density, 1.0148;
buffer viscosity, 0.0106. This model ﬁts the data to the Lamm equa-
tion. The reliability of the analysis was conﬁrmed by the goodness
of ﬁt (root-mean-square deviation [RMSD]).
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